JP2013506622A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013506622A5 JP2013506622A5 JP2012525756A JP2012525756A JP2013506622A5 JP 2013506622 A5 JP2013506622 A5 JP 2013506622A5 JP 2012525756 A JP2012525756 A JP 2012525756A JP 2012525756 A JP2012525756 A JP 2012525756A JP 2013506622 A5 JP2013506622 A5 JP 2013506622A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- antigen
- binding portion
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090001123 antibodies Proteins 0.000 claims 33
- 102000004965 antibodies Human genes 0.000 claims 33
- 239000000427 antigen Substances 0.000 claims 20
- 102000038129 antigens Human genes 0.000 claims 20
- 108091007172 antigens Proteins 0.000 claims 20
- 101700073818 CDR1 Proteins 0.000 claims 14
- 102100002977 CDR1 Human genes 0.000 claims 14
- 108060001277 CDR2 Proteins 0.000 claims 14
- 102100008744 CDR2 Human genes 0.000 claims 14
- 101700027814 CDR3 Proteins 0.000 claims 14
- 210000004027 cells Anatomy 0.000 claims 8
- 108010045030 monoclonal antibodies Proteins 0.000 claims 8
- 102000005614 monoclonal antibodies Human genes 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 5
- 230000035772 mutation Effects 0.000 claims 5
- 150000003384 small molecules Chemical class 0.000 claims 5
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 4
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 claims 4
- 206010069755 K-ras gene mutation Diseases 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 108020004705 Codon Proteins 0.000 claims 2
- 230000035693 Fab Effects 0.000 claims 2
- 102100009279 KRAS Human genes 0.000 claims 2
- 101710033922 KRAS Proteins 0.000 claims 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- 210000004688 Microtubules Anatomy 0.000 claims 2
- 102000028664 Microtubules Human genes 0.000 claims 2
- 108091022031 Microtubules Proteins 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 108091006028 chimera Proteins 0.000 claims 2
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 claims 2
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229960001230 Asparagine Drugs 0.000 claims 1
- 108010022830 Cetuximab Proteins 0.000 claims 1
- 102000015550 Cyclin-dependent kinase inhibitor Human genes 0.000 claims 1
- 108050004829 Cyclin-dependent kinase inhibitor Proteins 0.000 claims 1
- 229960001433 Erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 102100014263 IGF1R Human genes 0.000 claims 1
- 101700025802 IGF1R Proteins 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 102100000087 LARP6 Human genes 0.000 claims 1
- 101700066207 LARP6 Proteins 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 102100019471 PIK3CA Human genes 0.000 claims 1
- 101710027440 PIK3CA Proteins 0.000 claims 1
- 229960001592 Paclitaxel Drugs 0.000 claims 1
- 108010061219 Panitumumab Proteins 0.000 claims 1
- 108010010691 Trastuzumab Proteins 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- -1 hormone therapy Substances 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 239000003197 protein kinase b inhibitor Substances 0.000 claims 1
- 239000000007 protein synthesis inhibitor Substances 0.000 claims 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229930003347 taxol Natural products 0.000 claims 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 210000004881 tumor cells Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23579909P | 2009-08-21 | 2009-08-21 | |
| US61/235,799 | 2009-08-21 | ||
| PCT/US2010/046364 WO2011022727A2 (en) | 2009-08-21 | 2010-08-23 | Antibodies against the ectodomain of erbb3 and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013506622A JP2013506622A (ja) | 2013-02-28 |
| JP2013506622A5 true JP2013506622A5 (pt) | 2013-10-10 |
| JP5752687B2 JP5752687B2 (ja) | 2015-07-22 |
Family
ID=43607614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012525756A Ceased JP5752687B2 (ja) | 2009-08-21 | 2010-08-23 | Ｅｒｂｂ３の外部ドメインに対する抗体およびその使用 |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP2467164A2 (pt) |
| JP (1) | JP5752687B2 (pt) |
| KR (1) | KR20120059568A (pt) |
| CN (1) | CN103002912A (pt) |
| AU (1) | AU2010284018C1 (pt) |
| BR (1) | BR112012003809A2 (pt) |
| CA (1) | CA2771744A1 (pt) |
| CR (1) | CR20120108A (pt) |
| DO (1) | DOP2012000044A (pt) |
| EA (1) | EA201200195A1 (pt) |
| EC (1) | ECSP12011740A (pt) |
| IL (1) | IL218097A0 (pt) |
| IN (1) | IN2012DN01518A (pt) |
| MA (1) | MA33582B1 (pt) |
| MX (1) | MX336091B (pt) |
| NI (1) | NI201200027A (pt) |
| PE (1) | PE20121585A1 (pt) |
| SG (1) | SG178509A1 (pt) |
| TN (1) | TN2012000057A1 (pt) |
| WO (1) | WO2011022727A2 (pt) |
| ZA (1) | ZA201201195B (pt) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2716301T (pt) | 2007-02-16 | 2017-07-04 | Merrimack Pharmaceuticals Inc | Anticorpos contra erbb3 e suas utilizações |
| ES2647466T3 (es) * | 2009-11-13 | 2017-12-21 | Daiichi Sankyo Europe Gmbh | Materiales y métodos para tratar o prevenir las enfermedades asociadas a HER-3 |
| JP5680671B2 (ja) | 2009-12-22 | 2015-03-04 | ロシュ グリクアート アーゲー | 抗ｈｅｒ３抗体及びその使用 |
| AU2011224186C1 (en) | 2010-03-11 | 2015-04-02 | Merrimack Pharmaceuticals, Inc. | Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| BR112012025730B1 (pt) | 2010-04-09 | 2020-12-08 | Aveo Pharmaceuticals, Inc | anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão |
| UA114883C2 (uk) | 2010-08-20 | 2017-08-28 | Новартіс Аг | Антитіло до рецептора епідермального фактора росту-3 (her3) |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| IT1402149B1 (it) * | 2010-10-04 | 2013-08-28 | Ist Fisioterap Ospitalroma | Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2. |
| JP6033783B2 (ja) | 2010-11-01 | 2016-11-30 | シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ | Ｐａｎ−ｈｅｒ抗体組成物 |
| ES2625818T3 (es) | 2011-04-19 | 2017-07-20 | Merrimack Pharmaceuticals, Inc. | Anticuerpos biespecíficos anti-IGF-1R y anti-ErbB3 |
| AU2012274461A1 (en) * | 2011-06-20 | 2014-01-16 | Kyowa Hakko Kirin Co., Ltd. | Anti-erbB3 antibody |
| US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
| BR112014007382A2 (pt) | 2011-09-30 | 2017-04-04 | Regeneron Pharma | anticorpos anti-erbb3 e seus usos |
| CA2851314A1 (en) | 2011-10-06 | 2013-04-11 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-erbb3 antibodies |
| WO2013071058A1 (en) * | 2011-11-09 | 2013-05-16 | The Uab Research Foundation | Her3 antibodies and uses thereof |
| BR112014013412A8 (pt) | 2011-12-05 | 2021-06-08 | Novartis Ag | anticorpos para o receptor 3 do fator de crescimento epidérmico (her3), e seus usos |
| WO2013124297A1 (en) * | 2012-02-22 | 2013-08-29 | U3 Pharma Gmbh | Combination of hb-egf binding protein and egfr inhibitor |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| US20160232293A1 (en) * | 2013-10-17 | 2016-08-11 | Sanford-Burnham Medical Research Institute | Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers |
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| US10844127B2 (en) * | 2014-02-28 | 2020-11-24 | Merus N.V. | Antibodies that bind EGFR and ErbB3 |
| CN105367657B (zh) * | 2014-08-14 | 2019-09-13 | 上海生物制品研究所有限责任公司 | 抗her3抗体、其制法及其应用 |
| CA2959716A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
| JP2017534574A (ja) | 2014-09-08 | 2017-11-24 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． | チロシンキナーゼ阻害薬（ｔｋｉ）に耐性のがんを処置するための組成物および方法 |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| KR20180100305A (ko) | 2015-10-23 | 2018-09-10 | 메뤼스 엔.페. | 암 성장을 억제하는 결합 분자 |
| SG11201908971RA (en) | 2017-03-31 | 2019-10-30 | Merus Nv | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene |
| US11390686B2 (en) | 2017-08-09 | 2022-07-19 | University Of Saskatchewan | HER3 binding agents and uses thereof |
| CN111094351B (zh) | 2017-08-09 | 2024-07-12 | 美勒斯公司 | 结合EGFR和cMET的抗体 |
| GB201804094D0 (en) * | 2018-03-14 | 2018-04-25 | Ultrahuman Thirteen Ltd | ERBB3 Binding agents |
| US20210246223A1 (en) * | 2018-06-22 | 2021-08-12 | Crd Pharmaceuticals Inc | ANTI-HER3 Antibody and uses thereof |
| TW202304983A (zh) * | 2020-10-14 | 2023-02-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｈｅｒ３抗體和抗ｈｅｒ３抗體藥物偶聯物及其醫藥用途 |
| WO2023198138A1 (zh) * | 2022-04-13 | 2023-10-19 | 上海翰森生物医药科技有限公司 | 抗体或其抗原结合片段及其医药用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2716301T (pt) * | 2007-02-16 | 2017-07-04 | Merrimack Pharmaceuticals Inc | Anticorpos contra erbb3 e suas utilizações |
-
2010
- 2010-08-23 CN CN2010800477186A patent/CN103002912A/zh active Pending
- 2010-08-23 PE PE2012000234A patent/PE20121585A1/es not_active Application Discontinuation
- 2010-08-23 MX MX2012002172A patent/MX336091B/es unknown
- 2010-08-23 BR BR112012003809A patent/BR112012003809A2/pt not_active IP Right Cessation
- 2010-08-23 IN IN1518DEN2012 patent/IN2012DN01518A/en unknown
- 2010-08-23 KR KR1020127007280A patent/KR20120059568A/ko not_active Application Discontinuation
- 2010-08-23 SG SG2012011664A patent/SG178509A1/en unknown
- 2010-08-23 EA EA201200195A patent/EA201200195A1/ru unknown
- 2010-08-23 WO PCT/US2010/046364 patent/WO2011022727A2/en active Application Filing
- 2010-08-23 CA CA2771744A patent/CA2771744A1/en not_active Abandoned
- 2010-08-23 JP JP2012525756A patent/JP5752687B2/ja not_active Ceased
- 2010-08-23 AU AU2010284018A patent/AU2010284018C1/en not_active Ceased
- 2010-08-23 EP EP10810721A patent/EP2467164A2/en not_active Withdrawn
-
2012
- 2012-02-09 TN TNP2012000057A patent/TN2012000057A1/en unknown
- 2012-02-14 IL IL218097A patent/IL218097A0/en unknown
- 2012-02-15 NI NI201200027A patent/NI201200027A/es unknown
- 2012-02-17 ZA ZA2012/01195A patent/ZA201201195B/en unknown
- 2012-02-20 DO DO2012000044A patent/DOP2012000044A/es unknown
- 2012-03-05 CR CR20120108A patent/CR20120108A/es unknown
- 2012-03-12 MA MA34684A patent/MA33582B1/fr unknown
- 2012-03-21 EC ECSP12011740 patent/ECSP12011740A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013506622A5 (pt) | ||
| KR102068600B1 (ko) | Pdl-1 항체, 그 약학적 조성물 및 그 용도 | |
| US10058610B2 (en) | Methods for treating cancer by administering humanized pan-HER antibody compositions | |
| EP3470435B1 (en) | Antibody that binds erbb-2 and erbb-3 | |
| CN102421802B (zh) | 人源化的axl抗体 | |
| JP2020520370A (ja) | 抗ＳＩＲＰα抗体 | |
| JP2017149720A5 (pt) | ||
| TW201542594A (zh) | 雙特異性ｈｅｒ２抗體 | |
| BR112015011518B1 (pt) | Anticorpo heterodimérico, ácido nucleico e vetor | |
| JP2010518820A5 (pt) | ||
| EA031184B1 (ru) | БИСПЕЦИФИЧЕСКИЕ К EGFR/c-Met АНТИТЕЛА | |
| JP2014522850A5 (pt) | ||
| JP2020514277A5 (pt) | ||
| JP2020513759A5 (pt) | ||
| US20200339702A1 (en) | De-immunised anti-erbb3 antibodies | |
| TW202241944A (zh) | 新穎的抗ｇｒｅｍｌｉｎ１抗體 | |
| JP7065935B2 (ja) | 抗ｌｙ６ｇ６ｄ抗体及び使用方法 | |
| CN109071671B (zh) | Erbb2靶向抗体 | |
| WO2023078386A1 (zh) | 抗cldn18.2抗体及其用途 | |
| US20230357391A1 (en) | Cd47 binding agents and uses thereof | |
| WO2023227115A1 (en) | A method of treating solid tumor | |
| US20210363273A1 (en) | Binding molecules for the treatment of cancer | |
| US20240294622A1 (en) | Novel anti-gremlin1 antibodies | |
| JPWO2021173832A5 (pt) | ||
| CN117202897A (zh) | 使用raf抑制剂和pd-1轴抑制剂的组合疗法 |